top of page
Search

Prolonged response to metastatic pancreatic cancer treated with pembrolizumab based on mismatch repa

Updated: Feb 6, 2021

Prolonged response to metastatic pancreatic cancer treated with pembrolizumab based on mismatch repair status characterized from next generation sequencing

Lan Ngo


 
 
 

Comments


bottom of page